MX2023005533A - Derivado de triazina diona, metodo de preparacion y aplicacion del mismo en medicina. - Google Patents
Derivado de triazina diona, metodo de preparacion y aplicacion del mismo en medicina.Info
- Publication number
- MX2023005533A MX2023005533A MX2023005533A MX2023005533A MX2023005533A MX 2023005533 A MX2023005533 A MX 2023005533A MX 2023005533 A MX2023005533 A MX 2023005533A MX 2023005533 A MX2023005533 A MX 2023005533A MX 2023005533 A MX2023005533 A MX 2023005533A
- Authority
- MX
- Mexico
- Prior art keywords
- preparation
- method therefor
- medicine
- application
- dione derivative
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 4
- 238000002360 preparation method Methods 0.000 title abstract 3
- BFGQTWYXWNCTSX-UHFFFAOYSA-N triazine-4,5-dione Chemical class O=C1C=NN=NC1=O BFGQTWYXWNCTSX-UHFFFAOYSA-N 0.000 title abstract 3
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 abstract 3
- 229940122960 Myosin inhibitor Drugs 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 208000019622 heart disease Diseases 0.000 abstract 1
- 230000001991 pathophysiological effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/42—One nitrogen atom
- C07D251/46—One nitrogen atom with oxygen or sulfur atoms attached to the two other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011310827 | 2020-11-20 | ||
| CN202110021509 | 2021-01-08 | ||
| CN202110244090 | 2021-03-05 | ||
| CN202110464375 | 2021-04-28 | ||
| PCT/CN2021/131642 WO2022105852A1 (zh) | 2020-11-20 | 2021-11-19 | 三嗪二酮类衍生物、其制备方法及其在医药上的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023005533A true MX2023005533A (es) | 2023-05-25 |
Family
ID=81708401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023005533A MX2023005533A (es) | 2020-11-20 | 2021-11-19 | Derivado de triazina diona, metodo de preparacion y aplicacion del mismo en medicina. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240010639A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4249474A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7849587B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230110538A (cg-RX-API-DMAC7.html) |
| CN (4) | CN119638681A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021381664B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3198934A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023005533A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202227420A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022105852A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA53491A (fr) | 2018-08-31 | 2021-09-15 | Cytokinetics Inc | Inhibiteurs de sarcomes cardiaques |
| IL325304A (en) * | 2018-10-29 | 2026-02-01 | Myokardia Inc | 4-Tetrahydropyran-4-yl-6-fluoro-7-phenyl-8,7,6,5-tetrahydro-h1-pyrido[3,2-d]pyrimidine-2,4-dione |
| KR20240015622A (ko) | 2021-03-04 | 2024-02-05 | 싸이토키네틱스, 인코포레이티드 | 심장 근절 억제제 |
| TW202302541A (zh) * | 2021-03-17 | 2023-01-16 | 美商翰森生物有限責任公司 | 含氮雜環酮、其製備方法和醫藥用途 |
| EP4370116B1 (en) | 2021-07-16 | 2025-01-15 | Cytokinetics, Inc. | Aficamten dosage regimens for treating obstructive hypertrophic cardiomyopathy |
| CN117088854A (zh) * | 2022-05-20 | 2023-11-21 | 江苏恒瑞医药股份有限公司 | 一种三嗪二酮类衍生物的可药用盐、晶型及制备方法 |
| WO2023222103A1 (zh) | 2022-05-20 | 2023-11-23 | 江苏恒瑞医药股份有限公司 | 一种三嗪二酮类衍生物的晶型及制备方法 |
| WO2024056096A1 (zh) * | 2022-09-16 | 2024-03-21 | 江苏豪森药业集团有限公司 | 一种含氮杂环酮化合物的晶型及其制备方法 |
| WO2026130464A1 (zh) * | 2024-12-18 | 2026-06-25 | 江苏恒瑞医药股份有限公司 | 制备治疗肥厚型心肌病药物的用途 |
| WO2026153470A1 (zh) * | 2025-01-16 | 2026-07-23 | 江苏恒瑞医药股份有限公司 | 制备治疗非梗阻性肥厚型心肌病药物的用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5502089B2 (ja) * | 2008-10-09 | 2014-05-28 | エフ.ホフマン−ラ ロシュ アーゲー | アミロイドβのモジュレーター |
| SG173647A1 (en) * | 2009-02-13 | 2011-10-28 | Shionogi & Co | Novel triazine derivative and pharmaceutical composition containing same |
| US20110319400A1 (en) * | 2010-06-28 | 2011-12-29 | Flores Christopher M | Prokineticin 1 receptor antagonists for the treatment of pain |
| US9718790B2 (en) * | 2010-08-10 | 2017-08-01 | Shionogi & Co., Ltd. | Triazine derivative and pharmaceutical composition having an analgesic activity comprising the same |
| US9199945B2 (en) | 2013-06-21 | 2015-12-01 | MyoKardia, Inc. | Cycloalkyl-substituted pyrimidinedione compounds |
| SMT202000071T1 (it) | 2013-06-21 | 2020-03-13 | Myokardia Inc | Composti di pirimidinadione contro le condizioni cardiache |
| US9663516B2 (en) * | 2014-12-18 | 2017-05-30 | MyoKardia, Inc. | Bicyclic-pyrimidinedione compounds |
| JP7042812B2 (ja) | 2016-06-20 | 2022-03-28 | ノバルティス アーゲー | トリアゾロピリミジン化合物の結晶形態 |
| JP7412328B2 (ja) | 2017-07-24 | 2024-01-12 | ノバルティス アーゲー | Nlrp活性に関連する状態を治療するための化合物及び組成物 |
| IL322175A (en) | 2017-08-04 | 2025-09-01 | Myokardia Inc | Treatment of hypertrophic cardiomyopathy (HCM) with pyrimidinedione compounds |
| CN111094300B (zh) * | 2018-01-31 | 2022-09-16 | 江苏恒瑞医药股份有限公司 | 苯并杂芳基类衍生物、其制备方法及其在医药上的应用 |
| MA53491A (fr) * | 2018-08-31 | 2021-09-15 | Cytokinetics Inc | Inhibiteurs de sarcomes cardiaques |
| IL325304A (en) | 2018-10-29 | 2026-02-01 | Myokardia Inc | 4-Tetrahydropyran-4-yl-6-fluoro-7-phenyl-8,7,6,5-tetrahydro-h1-pyrido[3,2-d]pyrimidine-2,4-dione |
| WO2020151605A1 (zh) * | 2019-01-25 | 2020-07-30 | 青岛吉澳医药科技有限公司 | 氘代苯甲氨嘧啶二酮衍生物及其用途 |
| CN110698415B (zh) | 2019-10-21 | 2023-05-09 | 上海先行医药开发有限公司 | 一种肌球蛋白抑制剂及其制备方法和用途 |
| TW202302541A (zh) * | 2021-03-17 | 2023-01-16 | 美商翰森生物有限責任公司 | 含氮雜環酮、其製備方法和醫藥用途 |
-
2021
- 2021-11-19 EP EP21893999.9A patent/EP4249474A4/en active Pending
- 2021-11-19 AU AU2021381664A patent/AU2021381664B2/en active Active
- 2021-11-19 CA CA3198934A patent/CA3198934A1/en active Pending
- 2021-11-19 CN CN202411649375.0A patent/CN119638681A/zh active Pending
- 2021-11-19 WO PCT/CN2021/131642 patent/WO2022105852A1/zh not_active Ceased
- 2021-11-19 KR KR1020237019549A patent/KR20230110538A/ko active Pending
- 2021-11-19 JP JP2023530323A patent/JP7849587B2/ja active Active
- 2021-11-19 CN CN202180065655.5A patent/CN116323598B/zh active Active
- 2021-11-19 CN CN202411649482.3A patent/CN119638682A/zh active Pending
- 2021-11-19 TW TW110143208A patent/TW202227420A/zh unknown
- 2021-11-19 US US18/253,704 patent/US20240010639A1/en active Pending
- 2021-11-19 MX MX2023005533A patent/MX2023005533A/es unknown
- 2021-11-19 CN CN202411649280.9A patent/CN119638680A/zh active Pending
-
2026
- 2026-02-12 JP JP2026021203A patent/JP2026097848A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3198934A1 (en) | 2022-05-27 |
| AU2021381664A1 (en) | 2023-06-15 |
| JP2023550444A (ja) | 2023-12-01 |
| KR20230110538A (ko) | 2023-07-24 |
| CN116323598B (zh) | 2024-11-15 |
| CN119638680A (zh) | 2025-03-18 |
| EP4249474A4 (en) | 2024-04-17 |
| CN119638682A (zh) | 2025-03-18 |
| EP4249474A1 (en) | 2023-09-27 |
| WO2022105852A1 (zh) | 2022-05-27 |
| CN116323598A (zh) | 2023-06-23 |
| US20240010639A1 (en) | 2024-01-11 |
| AU2021381664B2 (en) | 2026-05-28 |
| JP2026097848A (ja) | 2026-06-16 |
| JP7849587B2 (ja) | 2026-04-22 |
| TW202227420A (zh) | 2022-07-16 |
| CN119638681A (zh) | 2025-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2026005655A2 (es) | Inhibidor de pan-kras y uso del mismo en medicinas | |
| MX2023015533A (es) | Compuesto tetraciclico fusionado, metodo de preparacion y aplicacion en medicina. | |
| MX2025001995A (es) | Compuesto heterociclico, procedimiento para prepararlo y uso farmaceutico del mismo | |
| MX2023013890A (es) | Compuesto heterociclico que contiene nitrogeno, metodo de preparacion del mismo y aplicacion del mismo en medicamentos. | |
| SG160364A1 (en) | Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer | |
| BRPI0512075A (pt) | composto, processo para a preparação do mesmo, composição farmacêutica, uso de um composto, e, métodos para a produção de um efeito inibidor de b-raf, e de um efeito anticáncer em um animal de sangue quente, e para o tratamento de uma doença | |
| EA200970611A1 (ru) | Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы | |
| DK2324008T3 (da) | Diarylpyrazol som protein kinase inhibitorer | |
| NO20076425L (no) | Fremgangsmater for behandling av drug-resistent cancer | |
| BRPI0517426A (pt) | composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito anti-proliferação celular, para produzir um efeito inibitório de cdk2, e para tratar uma doença em um animal de sangue quente | |
| MXPA05007857A (es) | Moduladores derivados de indol de receptores nucleares de hormonas esteroideas. | |
| MX2023011166A (es) | Compuesto de tetrahidronaftaleno, metodo de preparacion y uso del mismo en medicina. | |
| EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
| RU2010123028A (ru) | Кортикостероиды для лечения диареи, индуцированной эпотилоном или производным эпотилона | |
| PH12021551232A1 (en) | Haloallylamine compounds and application thereof | |
| WO2022079290A3 (en) | Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof | |
| ZA202501471B (en) | Preparation and use of quinazolinone derivative as kinase inhibitor | |
| BRPI0411503A (pt) | composto, composição farmacêutica, uso de um composto, método de tratar um ser humano que sofre de uma doença hiperproliferativa tal como cáncer, e, processo para a preparação de um composto | |
| EP4700016A3 (en) | Pharmaceutical agent for treating amyotrophic lateral sclerosis or suppressing disease progress thereof | |
| RU2013148817A (ru) | Комбинации соединений-ингибиторов акт и мек и способы их применения | |
| JOP20240217A1 (ar) | مشتقات الكوينولين كمُعدِّلات للعضو x2 لمستقبل بروتين g مرتبط بـ mas ومنتجات ذات صلة | |
| MX2024011705A (es) | Compuesto heterociclico que contiene nitrogeno, metodo de preparacion y aplicacion farmaceutica | |
| MX2023010673A (es) | Cetonas heterociclicas que contienen nitrogeno, metodos de preparacion y usos medicinales de las mismas. | |
| MX2026001837A (es) | Compuestos que contienen ciclobutilo | |
| WO2009019708A3 (en) | Pharmaceutical compositions and methods for the treatment of cancer |